The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Open accessAbstract
Objective: Develop a cerebrospinal fluid biomarker signature for mild Alzheimer's disease (AD) in Alzheimer's Disease Neuroimaging Initiative (ADNI) subjects. Methods: Amyloid‐β 1 to 42 peptide (Aβ 1–42), total tau (t‐tau), and tau phosphorylated at the threonine 181 were measured in (1) cerebrospinal fluid (CSF) samples obtained during baseline evaluation of 100 mild AD, 196 mild cognitive impairment, and 114 elderly cognitively normal (NC) subjects in ADNI; and (2) independent 56 autopsy‐confirmed AD cases and 52 age‐matched elderly NCs using a multiplex immunoassay. Detection of an AD CSF profile for t‐tau and Aβ 1–42 in ADNI subjects was achieved using receiver operating characteristic cut points and logistic regression models derived from the autopsy‐confirmed CSF data. Results: CSF Aβ 1–42 was the most sensitive biomarker for AD in the autopsy cohort of CSF samples: receiver operating characteristic area under the curve of 0.913 and sensitivity for AD detection of 96.4%. In the ADNI cohort, a logistic regression model for Aβ 1–42, t‐tau, and APO ε 4 allele count provided the best assessment delineation of mild AD. An AD‐like baseline CSF profile for t‐tau/Aβ 1–42 was detected in 33 of 37 ADNI mild cognitive impairment subjects who converted to probable AD during the first year of the study. Interpretation: The CSF biomarker signature of AD defined by Aβ 1–42 and t‐tau in the autopsy‐confirmed AD cohort and confirmed in the cohort followed in ADNI for 12 months detects mild AD in a large, multisite, prospective clinical investigation, and this signature appears to predict conversion from mild cognitive impairment to AD. Ann Neurol 2009
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A preponderance of evidence supports the interpretation that PIB uptake and CSF Aβ42 are reliable surrogate markers of amyloid plaque pathology in living subjects (15-19).”
From Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance (2011) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Increased concentrations of extracellular soluble phosphorylated tau (p-tau) and total tau (t-tau) constitute a reliable index of this intracellular process in mild cognitive impairment due to AD2,3 and AD dementia.2,4”
From Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease (2022) · cites this paper as [4]
Experimental — accuracy not yet measuredIn the citing paper
“Abnormal CSF Aβ42 values were defined using the previously established cut-off of <192 ng/L57–59.”
From Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity (2017) · cites this paper as [57]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700
Self-citationCSF markers for incipient Alzheimer's disease
Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291
Self-citationMueller, S. G., Weiner, M. W., Thal, L. J., Petersen, R. C., Jack, C. R., Jagust, W., Trojanowski, J. Q., Toga, A. W., & Beckett, L. (2005) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2005.06.003 · Cited by 1,233
Self-citationFagan, A. M., Roe, C. M., Xiong, C., Mintun, M. A., Morris, J. C., & Holtzman, D. M. (2007) · Archives of Neurology · doi:10.1001/archneur.64.3.noc60123 · Cited by 897
Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases
Selkoe, D. J. (2004) · Nature Cell Biology · doi:10.1038/ncb1104-1054 · Cited by 863
Consensus Report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease”
The Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and, & National Institute on Aging Working Group (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00022-0 · Cited by 719
Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs
Forman, M. S., Trojanowski, J. Q., & Lee, V. M.-Y. (2004) · Nature Medicine · doi:10.1038/nm1113 · Cited by 715
Self-citationSunderland, T., Linker, G., Mirza, N., Putnam, K. T., Friedman, D. L., Kimmel, L. H., Bergeson, J., Manetti, G. J., Zimmermann, M., Tang, B., et al. (2003) · JAMA · doi:10.1001/jama.289.16.2094 · Cited by 656
Frontotemporal dementia: Clinicopathological correlations
Forman, M. S., Farmer, J., Johnson, J. K., Clark, C. M., Arnold, S. E., Coslett, H. B., Chatterjee, A., Hurtig, H. I., Karlawish, J. H., Rosen, H. J., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20873 · Cited by 478
Self-citationGalasko, D., Chang, L., Motter, R., Clark, C. M., Kaye, J., Knopman, D., Thomas, R., Kholodenko, D., Schenk, D., Lieberburg, I., et al. (1998) · Archives of Neurology · doi:10.1001/archneur.55.7.937 · Cited by 442
Self-citation
Research works printed but not linked: 1
- 10.1016/S1474-4422(03)00530-1 · DOI · Paper page
Cited by
Sorted by citations
Items 501–600 of 1,012
Reduced sample sizes for atrophy outcomes in Alzheimer's disease trials: baseline adjustment
Schott, J. M., Bartlett, J. W., Barnes, J., Leung, K. K., Sebastien Ourselin, A., & Fox, N. C. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.011 · Cited by 82
Horgusluoglu, E., Nho, K. T., Risacher, S. L., Kim, S., Foroud, T., Shaw, L. M. J., Trojanowski, J. Q., Aisen, P. S. S., Petersen, R. C., Jack, C. R., et al. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.08.010 · Cited by 81
Self-citationRoss, J., Sharma, S., Winston, J., Nunez, M., Bottini, G., Franceschi, M., Scarpini, E. A., Frigerio, E., Fiorentini, F., Fernández, M., et al. (2013) · Current Alzheimer Research · doi:10.2174/13892037113149990144 · Cited by 78
Irwin, D. J., Lleó, A., Xie, S. X., McMillan, C. T., Wolk, D. A., Lee, E. B., Van Deerlin, V. M., Shaw, L. M., Trojanowski, J. Q., & Grossman, M. (2017) · Annals of Neurology · doi:10.1002/ana.24996 · Cited by 67
Self-citationA 2-Step Cerebrospinal Algorithm for the Selection of Frontotemporal Lobar Degeneration Subtypes
Lleó, A., Irwin, D. J., Illán-Gala, I., McMillan, C. T., Wolk, D. A., Lee, E. B., Van Deerlin, V. M., Shaw, L. M., Trojanowski, J. Q., & Grossman, M. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.0118 · Cited by 71
Self-citationTau oligomers in cerebrospinal fluid in Alzheimer's disease
Sengupta, U., Portelius, E., Hansson, O., Farmer, K., Castillo‐Carranza, D., Woltjer, R., Zetterberg, H., Galasko, D., Blennow, K., & Kayed, R. (2017) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.382 · Cited by 77
Self-citationA Luminex Assay Detects Amyloid β Oligomers in Alzheimer’s Disease Cerebrospinal Fluid
Herskovits, A. Z., Locascio, J. J., Peskind, E. R., Li, G., & Hyman, B. T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067898 · Cited by 77
Korecka, M., & Shaw, L. M. J. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15465 · Cited by 82
Self-citationBiomarkers in Amyloid-β Immunotherapy Trials in Alzheimer’s Disease
Blennow, K., Hampel, H. J., & Zetterberg, H. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.154 · Cited by 83
Self-citationInsel, P. S., Ossenkoppele, R., Gessert, D., Jagust, W., Landau, S. M., Hansson, O., Weiner, M. W., & Mattsson, N. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00281 · Cited by 75
Longitudinal Cerebrospinal Fluid Biomarkers over Four Years in Mild Cognitive Impairment
Mattsson, N., Portelius, E., Rolstad, S., Gustavsson, M. K., Andréasson, U., Stridsberg, M., Wallin, A., Blennow, K., & Zetterberg, H. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120019 · Cited by 75
Self-citationBlennow, K., & Zetterberg, H. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00345 · Cited by 79
Self-citationPutcha, D., Brickhouse, M. J., Wolk, D. A., & Dickerson, B. C. (2019) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2019.03.015 · Cited by 80
Longitudinal atrophy in early Braak regions in preclinical Alzheimer's disease
Xie, L., Wisse, L. E. M., Das, S. R., Vergnet, N., Dong, M., Ittyerah, R., de Florès, R., Yushkevich, P. A., Wolk, D. A., & Initiative, A. D. N. (2020) · Human Brain Mapping · doi:10.1002/hbm.25151 · Cited by 66
Self-citationRami, L., Fortea, J., Bosch, B., Solé‐Padullés, C., Lladó, A., Iranzo, Á., Sánchez‐Valle, R., & Molinuevo, J. L. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-101422 · Cited by 83
Influence of age, disease onset and ApoE4 on visual medial temporal lobe atrophy cut‐offs
Pereira, J. B., Cavallin, L., Spulber, G., Aguilar, C., Mecocci, P., Vellas, B. J., Tsolaki, M., Kłoszewska, I., Soininen, H. S., Spenger, C., et al. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12148 · Cited by 80
Wang, L., Leung, Y. Y., Chang, S.-K., Leight, S., Knapik-Czajka, M. E., Baek, Y., Shaw, L. M. J., Lee, V. M. ‐., Trojanowski, J. Q., & Clark, C. M. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120082 · Cited by 78
Self-citationLi, Q., Villemagne, V. L., Doecke, J. D., Rembach, A., Sarros, S., Varghese, S., McGlade, A. R., Laughton, K. M., Pertile, K. K., Fowler, C. J., et al. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150247 · Cited by 75
Frölich, L., Peters, O., Lewczuk, P., Gruber, O., Teipel, S. J., Gertz, H., Jahn, H., Jessen, F., Kurz, A., Luckhaus, C., et al. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0301-7 · Cited by 82
Self-citationdel Campo, M., Vermunt, L., Peeters, C. F. W., Sieben, A., Hok‐A‐Hin, Y. S., Lleó, A., Alcolea, D. A., van Nee, M. M., Engelborghs, S., van Alphen, J. L., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41122-y · Cited by 82
Increased Myeloperoxidase Plasma Levels in Patients with Alzheimer's Disease
Tzikas, S., Schlak, D., Sopova, K., Gatsiou, A., Stakos, D., Stamatelopoulos, K. S., Stellos, K., & Laske, C. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-131469 · Cited by 75
Intersite variability of CSF Alzheimer's disease biomarkers in clinical setting
Dumurgier, J., Vercruysse, O., Paquet, C., Bombois, S., Chaulet, C., Laplanche, J., Peoc’h, K., Schraen‐Maschke, S., Pasquier, F., Touchon, J., et al. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.06.006 · Cited by 75
Okonkwo, O. C. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.118 · Cited by 78
Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease
Ng, K. P., Pascoal, T. A., Mathotaarachchi, S. S., Chung, C.-O., Benedet, A. L., Shin, M., Kang, M. S., Li, X., Ba, M., Kandiah, N., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000003916 · Cited by 76
Self-citationA potential endophenotype for Alzheimer's disease: cerebrospinal fluid clusterin
Deming, Y., Xia, J., Cai, Y., Lord, J., Holmans, P., Bertelsen, S., Holtzman, D., Morris, J. C., Bales, K., Pickering, E. H., et al. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.09.009 · Cited by 66
Schreiber, S., Landau, S. M., Fero, A., Schreiber, F., & Jagust, W. J. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.1633 · Cited by 79
Xu, W., Initiative, A. D. N., Zhang, C. M., Li, J., Tan, C., Cao, X., Tan, L., & Yu, J. (2019) · Aging · doi:10.18632/aging.101971 · Cited by 74
Self-citationCSF biomarkers in neurodegenerative diseases
Mattsson, N. (2011) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2011.082 · Cited by 75
β-Amyloid Dynamics in Human Plasma
Huang, Y., Potter, R. C., Sigurdson, W. C., Kasten, T. P., Connors, R., Morris, J. C., Benzinger, T. L. S., Mintun, M. A., Ashwood, T. J., Ferm, M. T., et al. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.18107 · Cited by 80
CSF soluble TREM2 as a measure of immune response along the Alzheimer's disease continuum
Rauchmann, B., Schneider-Axmann, T., Alexopoulos, P., & Perneczky, R. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.10.022 · Cited by 74
Plasma neuronal exosomal levels of Alzheimer's disease biomarkers in normal aging
Abner, E. L., Jicha, G. A., Shaw, L. M. J., Trojanowski, J. Q., & Goetzl, E. J. (2016) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.309 · Cited by 73
Self-citationYu, J., Li, J., Suckling, J., Feng, L., Pan, A., Wang, Y., Song, B., Zhu, S., Li, D., Wang, H.-F., et al. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2019.05.006 · Cited by 72
Self-citationRichard, E., Schmand, B. A., Eikelenboom, P., & Van Gool, W. A. (2013) · BMJ Open · doi:10.1136/bmjopen-2012-002541 · Cited by 84
Plasma Tau Association with Brain Atrophy in Mild Cognitive Impairment and Alzheimer’s Disease
Deters, K., Risacher, S. L., Kim, S., Nho, K. T., West, J. D., Blennow, K., Zetterberg, H., Shaw, L. M. J., Trojanowski, J. Q., Weiner, M. W., et al. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161114 · Cited by 72
Self-citationHey, J. A., Kočiš, P., Hort, J., Abushakra, S. R., Power, A., Vyhnálek, M., Yu, Y., & Tolar, M. (2018) · CNS Drugs · doi:10.1007/s40263-018-0554-0 · Cited by 76
Toden, S., Zhuang, J., Acosta, A. D., Karns, A. P., Salathia, N. S., Brewer, J. B., Wilcock, D. M., Aballi, J., Nerenberg, M. I., Quake, S. R., et al. (2020) · Science Advances · doi:10.1126/sciadv.abb1654 · Cited by 72
Britschgi, M., Rufibach, K., Huang, S. L. B., Clark, C. M., Kaye, J. A., Li, G., Peskind, E. R., Quinn, J. F., Galasko, D. R., & Wyss‐Coray, T. (2011) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m111.008862 · Cited by 73
Self-citationMeasurement of Blood Thiamine Metabolites for Alzheimer's Disease Diagnosis
Pan, X., Fei, G., Lu, J., Jin, L., Pan, S., Chen, Z., Wang, C., Sang, S., Liu, H., Hu, W., et al. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.11.039 · Cited by 74
Genome‐wide association study of Alzheimer's disease endophenotypes at prediagnosis stages
Chung, J., Wang, X., Maruyama, T., Ma, Y., Zhang, X., Mez, J., Sherva, R., Takeyama, H., Initiative, T. A. D. N., Lunetta, K. L., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.11.006 · Cited by 67
Johansson, P., Mattsson, N., Hansson, O., Wallin, A., Johansson, J.-O., Andréasson, U., Zetterberg, H., Blennow, K., & Svensson, J. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-101878 · Cited by 72
Self-citationEnrichment and Stratification for Predementia Alzheimer Disease Clinical Trials
Holland, D., McEvoy, L. K., Desikan, R. S., Dale, A. M., & Initiative, A. D. N. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047739 · Cited by 71
Self-citationFormaglio, M., Costes, N., Seguin, J., Tholance, Y., Bars, D. L., Roullet‐Solignac, I., Mercier, B., Krolak‐Salmon, P., & Vighetto, A. (2011) · Journal of Neurology · doi:10.1007/s00415-011-6030-0 · Cited by 72
Early identification and heritability of mild cognitive impairment
Kremen, W. S., Jak, A. J., Panizzon, M. S., Spoon, K. M., Franz, C. E., Thompson, W. K., Jacobson, K. C., Vasilopoulos, T., Vuoksimaa, E., Xian, H., et al. (2013) · International Journal of Epidemiology · doi:10.1093/ije/dyt242 · Cited by 70
(ADNI), T. A. D. N. I., Bouallègue, F. B., Mariano‐Goulart, D., & Payoux, P. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0260-z · Cited by 73
Emerging β-amyloid pathology and accelerated cortical atrophy
Mattsson, N., Insel, P. S., Nosheny, R., Tosun, D., Trojanowski, J. Q., Shaw, L. M., Jack, C. R., Donohue, M. C., & Weiner, M. W. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.446 · Cited by 71
Self-citationSchmand, B. A., Eikelenboom, P., van Gool, W. A., & Initiative, T. A. D. N. (2011) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2011.03539.x · Cited by 72
Hendrickson, R. C., Lee, A. Y. H., Song, Q., Liaw, A. I., Wiener, M., Paweletz, C. P., Seeburger, J. L., Li, J., Meng, F., Deyanova, E. G., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135365 · Cited by 68
Self-citationDerivation of a New ADAS-cog Composite Using Tree-based Multivariate Analysis
Llano, D. A., Laforet, G. A., & Devanarayan, V. (2010) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e3181f5b8d8 · Cited by 70
Biomarkers in pharmacology and drug discovery
Anderson, D. C., & Kodukula, K. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.08.026 · Cited by 72
Barnes, J., Carmichael, O. T., Leung, K. K., Schwarz, C. G., Ridgway, G. R., Bartlett, J. W., Malone, I. B., Schott, J. M., Rossor, M. N., Biessels, G. J., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.02.003 · Cited by 70
Initiative, A. D. N., Roostaei, T., Nazeri, A., Felsky, D., Jager, P. L. D., Schneider, J. A., Pollock, B. G., Bennett, D. A., & Voineskos, A. N. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.35 · Cited by 71
Self-citationLi, S., Lin, C.-W., Wei, K., Huang, C.-Y., Hsu, P., Liu, H.-L., Lin, Y.-J., Lin, S.-C., Yang, H., & Ma, C.-C. M. (2016) · Scientific Reports · doi:10.1038/srep25155 · Cited by 71
Tabarestani, S., Aghili, M., Eslami, M., Cabrerizo, M., Barreto, A. B., Rishe, N. D., Curiel, R. E., Loewenstein, D., Duara, R., & Adjouadi, M. (2019) · NeuroImage · doi:10.1016/j.neuroimage.2019.116317 · Cited by 72
Early diagnosis of Alzheimer's disease from elevated olfactory mucosal miR-206 level.
Moon, J., Lee, S.-T., Kong, I. G., Byun, J.-I., Sunwoo, J.-S., Shin, J.-W., Shim, J.-Y., Park, J.-H., Jeon, D., Jung, K.-H., et al. (2016) · Scientific Reports · doi:10.1038/srep20364 · Cited by 69
The application of cerebrospinal fluid biomarkers in early diagnosis of Alzheimer disease
Blennow, K., & Zetterberg, H. (2013) · Medical Clinics of North America · doi:10.1016/j.mcna.2012.12.012 · Cited by 69
Self-citationA Multilevel View of the Development of Alzheimer’s Disease
Ávila, J., & Perry, G. L. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2020.11.015 · Cited by 69
Leuzy, A., Ashton, N. J., Mattsson, N., Dodich, A., Boccardi, M., Corre, J., Drzezga, A. E., Nordberg, A. K., Ossenkoppele, R., Zetterberg, H., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05258-7 · Cited by 73
Self-citationLacsogram: A New EEG Tool to Diagnose Alzheimer's Disease
Rodrigues, P. M., Bispo, B. C., Garrett, C., Alves, D., Teixeira, J. P., & Freitas, D. (2021) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2021.3069789 · Cited by 69
Rosén, C., Mattsson, N., Johansson, P., Andréasson, U., Wallin, A., Hansson, O., Johansson, J.-O., Lamont, J. V., Svensson, J., Blennow, K., et al. (2011) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2011.00001 · Cited by 68
Self-citationThe relationship between complement factor C3, APOE ε4, amyloid and tau in Alzheimer’s disease
Initiative, A. D. N., Bonham, L. W., Desikan, R. S., & Yokoyama, J. S. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0339-y · Cited by 75
Self-citationWeight loss in the healthy elderly might be a non-cognitive sign of preclinical Alzheimer's disease
Jiménez, A., Initiative, T. A. D. N., Pegueroles, J., Carmona‐Iragui, M., Vilaplana, E., Montal, V., Alcolea, D. A., Videla, L., Illán‐Gala, I., Pané, A., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22218 · Cited by 69
Challenges associated with biomarker‐based classification systems for Alzheimer's disease
Illán‐Gala, I., Pegueroles, J., Montal, V., Vilaplana, E., Carmona‐Iragui, M., Alcolea, D., Dickerson, B. C., Sánchez‐Valle, R., de Leon, M. J., Blesa, R., et al. (2018) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2018.03.004 · Cited by 62
Self-citationTemporally Constrained Group Sparse Learning for Longitudinal Data Analysis in Alzheimer's Disease
Jie, B., Liu, M., Liu, J., Zhang, D., & Shen, D. G. (2016) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2016.2553663 · Cited by 68
Puangmalai, N., Sengupta, U., Bhatt, N., Gaikwad, S., Montalbano, M., Bhuyan, A., Garcia, S., McAllen, S., Sonawane, M., Jerez, C., et al. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.101766 · Cited by 68
Rami, L., Sala‐Llonch, R., Solé‐Padullés, C., Fortea, J., Olives, J., Lladó, A., Peña-Gómez, C., Balasa, M., Bosch, B., Antonell, A., et al. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120223 · Cited by 68
CSF Biomarkers for Amyloid and Tau Pathology in Alzheimer's Disease
Rosenmann, H. (2011) · Journal of Molecular Neuroscience · doi:10.1007/s12031-011-9665-5 · Cited by 72
Tau PET imaging predicts cognition in atypical variants of Alzheimer's disease
Phillips, J. S., Das, S. R., McMillan, C. T., Irwin, D. J., Roll, E. E., Da Re, F., Nasrallah, I. M., Wolk, D. A., & Grossman, M. (2018) · Human Brain Mapping · doi:10.1002/hbm.23874 · Cited by 68
Biomarkers in translational research of Alzheimer’s Disease
Tarawneh, R., & Holtzman, D. M. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.04.006 · Cited by 67
Free-water imaging of the hippocampus is a sensitive marker of Alzheimer's disease
Ofori, E., DeKosky, S. T., Febo, M., Colón-Pérez, L. M., Chakrabarty, P., Duara, R., Adjouadi, M., Golde, T. E., & Vaillancourt, D. E. (2019) · NeuroImage Clinical · doi:10.1016/j.nicl.2019.101985 · Cited by 64
A deep learning MRI approach outperforms other biomarkers of prodromal Alzheimer’s disease
Feng, X., Provenzano, F. A., Small, S. A., & Initiative, A. D. N. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-00985-x · Cited by 68
Self-citationLim, A. C., Barnes, L. L., Weissberger, G. H., Lamar, M., Nguyen, A. L., Fenton, L. E., Herrera, J., & Han, S. D. (2023) · Communications Medicine · doi:10.1038/s43856-023-00333-6 · Cited by 75
Lim, N. K.-H., Villemagne, V. L., Soon, C. P. W., Laughton, K. M., Rowe, C. C., McLean, C., Masters, C. L., Evin, G. M., & Li, Q. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-101974 · Cited by 67
White Matter Hyperintensities as Early and Independent Predictors of Alzheimer's Disease Risk
Mortamais, M., Artéro, S., & Ritchie, K. A. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-141473 · Cited by 69
Gomar, J. J., Conejero‐Goldberg, C., Davies, P., Goldberg, T. E., & Initiative, A. D. N. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.11.009 · Cited by 69
Self-citationEffects of Anesthetic Isoflurane and Desflurane on Human Cerebrospinal Fluid Aβ and τ Level
Zhang, B., Tian, M., Zheng, H., Yu, Z., Yue, Y., Li, T., Li, S., Marcantonio, E. R., & Xie, Z. (2013) · Anesthesiology · doi:10.1097/aln.0b013e31828ce55d · Cited by 67
Spampinato, M. V., Rumboldt, Z., Hosker, R. J., Mintzer, J. E., & Initiative, A. D. N. (2010) · Radiology · doi:10.1148/radiol.10100307 · Cited by 68
Self-citationLehallier, B., Essioux, L., Gayán, J., Alexandridis, R. A., Nikolcheva, T., Wyss‐Coray, T., Britschgi, M., & Initiative, A. D. N. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.3135 · Cited by 69
Self-citationPaterson, R. W., Heywood, W., Heslegrave, A., Magdalinou, N. K., Andréasson, U., Sirka, E., Bliss, E., Slattery, C. F., Toombs, J., Svensson, J., et al. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.194 · Cited by 65
Elevated Plasma Phosphorylated Tau 181 in Amyotrophic Lateral Sclerosis
Cousins, K. A. Q., Shaw, L. M. J., Shellikeri, S., Dratch, L., Rosario, L., Elman, L. B., Quinn, C. C., Amado, D. A., Wolk, D. A., Tropea, T. F., et al. (2022) · Annals of Neurology · doi:10.1002/ana.26462 · Cited by 66
Self-citationEwers, M., Schmitz, S., Hansson, O., Walsh, C., Fitzpatrick, A. L., Bennett, D. A., Minthon, L., Trojanowski, J. Q., Shaw, L. M. J., Faluyi, Y. O., et al. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.05.005 · Cited by 66
Self-citationCSF Apo-E levels associate with cognitive decline and MRI changes
Initiative, F. T. A. D. N., Toledo, J. B., Da, X., Weiner, M. W., Wolk, D. A., Xie, S. X., Arnold, S. E., Davatzikos, C., Shaw, L. M., & Trojanowski, J. Q. (2014) · Acta Neuropathologica · doi:10.1007/s00401-013-1236-0 · Cited by 71
Self-citationOperationalizing protocol differences for EADC‐ADNI manual hippocampal segmentation
Boccardi, M., Bocchetta, M., Ganzola, R., Robitaille, N., Redolfi, A., Duchesne, S., Jack, C. R., Frisoni, G. B., EADC‐ADNI Working Group on The Harmonized Protocol for Manual Hippocampal Segmentation and for the Alzheimer's Disease Neuroimaging Initiative, Bartzokis, G., et al. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.03.001 · Cited by 65
Cantero, J. L., Atienza, M., Lage, C., Záborszky, L., Vilaplana, E., López‐García, S., Pozueta, A., Rodríguez‐Rodríguez, E., Blesa, R., Alcolea, D. A., et al. (2019) · Cerebral Cortex · doi:10.1093/cercor/bhz224 · Cited by 65
Self-citationBanning, L. C. P., Ramakers, I. H. G. B., Köhler, S., Bron, E. E., Verhey, F. R. J., Deyn, P. P. D., Claassen, J. A. H. R., Koek, H. L., Middelkoop, H. A. M., van der Flier, W. M., et al. (2020) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2020.01.012 · Cited by 65
The cholinergic system in subtypes of Alzheimer’s disease: an in vivo longitudinal MRI study
Machado, A., Ferreira, D., Grothe, M. J., Eyjolfsdottir, H., Almqvist, P. M., Cavallin, L., Lind, G., Lind, G., Seiger, Å., Teipel, S., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00620-7 · Cited by 65
First amyloid β1‐42 certified reference material for re‐calibrating commercial immunoassays
Boulo, S., Kuhlmann, J., Andréasson, U., Brix, B., Venkataraman, I., Herbst, V., Rutz, S., Manuilova, E., Vandijck, M. L. J., Dekeyser, F., et al. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12145 · Cited by 65
Self-citationModeste, E. S., Ping, L., Watson, C. M., Duong, D. M., Dammer, E. B., Johnson, E. C. B., Roberts, B. R., Lah, J. J., Levey, A. I., & Seyfried, N. T. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00638-z · Cited by 66
Ventricular maps in 804 ADNI subjects: correlations with CSF biomarkers and clinical decline
Chou, Y.-Y., Leporé, N., Saharan, P., Madsen, S. K., Hua, X., Jack, C. R., Shaw, L. M. J., Trojanowski, J. Q., Weiner, M. W., Toga, A. W., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.05.001 · Cited by 66
Self-citationCerebral Microbleeds, CSF p-Tau, and Cognitive Decline: Significance of Anatomic Distribution
Chiang, G. C.-Y., Hernández, J. C. C., Kantarci, K., Jack, C. R., Weiner, M. W., & Initiative, A. D. N. (2015) · American Journal of Neuroradiology · doi:10.3174/ajnr.a4351 · Cited by 71
Self-citationPalmqvist, S., Insel, P. S., Zetterberg, H., Blennow, K., Brix, B., Stomrud, E., Initiative, T. A. D. N., study, T. S. B., Mattsson, N., & Hansson, O. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.08.014 · Cited by 65
Self-citationSchipke, C. G., Peters, O., Heuser, I., Grimmer, T., Sabbagh, M. N., Sabri, O., Hock, C., Kunz, M., Kuhlmann, J., Reininger, C. B., et al. (2012) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000339367 · Cited by 63
Developing the Resilience Framework for Nursing and Healthcare
Morse, J. M., Kent‐Marvick, J., Barry, L. A., Harvey, J., Okang, E. N., Rudd, E., Wang, C., & Williams, M. (2021) · Global Qualitative Nursing Research · doi:10.1177/23333936211005475 · Cited by 64
Luo, X., Hou, L., Shi, H., Zhong, X., Zhang, Y., Zheng, D., Tan, Y., Guoyan, H., Mu, N., Chan, J., et al. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12331 · Cited by 66
Johnston, J. M., Hu, W. T., Fardo, D. W., Greco, S. J., Perry, G. L., Montine, T. J., Trojanowski, J. Q., Shaw, L. M. J., Ashford, J. W., & Tezapsidis, N. (2014) · Current Alzheimer Research · doi:10.2174/1567205010666131212114156 · Cited by 64
Self-citationBertens, D., Knol, D. L., Scheltens, P., Visser, P. J., & Initiative, A. D. N. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.05.1754 · Cited by 70
Self-citationNettiksimmons, J., Harvey, D. J., Brewer, J. B., Carmichael, O. T., DeCarli, C. S., Jack, C. R., Petersen, R. C., Shaw, L. M. J., Trojanowski, J. Q., Weiner, M. W., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.025 · Cited by 64
Self-citationMicroRNA-135b has a neuroprotective role via targeting of β-site APP-cleaving enzyme 1
Zhang, Y., Xing, H., Guo, S., Zheng, Z., Wang, H., & Xu, D. (2016) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2016.3366 · Cited by 64
Scarano, S., Lisi, S., Ravelet, C., Peyrin, É., & Minunni, M. (2016) · Analytica Chimica Acta · doi:10.1016/j.aca.2016.08.008 · Cited by 67
Eppig, J. S., Edmonds, E. C., Campbell, L. M., Sanderson‐Cimino, M. E., Delano‐Wood, L., Bondi, M. W., & Initiative, A. D. N. (2017) · Journal of the International Neuropsychological Society · doi:10.1017/s135561771700039x · Cited by 66
Self-citationPadovani, A., Benussi, A., Cantoni, V., Dell’Era, V., Cotelli, M. S., Caratozzolo, S., Turrone, R., Rozzini, L., Alberici, A., Altomare, D., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180293 · Cited by 64
Metadata
- Authors
- Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., Dean, R., Siemers, E., Potter, W., Lee, V. M. ‐., Trojanowski, J. Q., & Initiative, A. D. N.
- Affiliations
- University of Pennsylvania (US)
- Fujirebio (Belgium) (BE)
- University of California San Diego (US)
- Mayo Clinic (US)
- University of Gothenburg (SE)
- Pfizer (United States) (US)
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Eli Lilly (United States) (US)
- Corresponding author
- Shaw, Leslie M.
- ORCID
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2009-04
- Volume
- 65
- Issue
- 4
- Pages
- 403-413
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- PMC
- PMC2696350
- OpenAlex
- W2008301592
- Cited by
- 2,065
- References
- 31
- Citations by year
- 2026: 59 · 2025: 82 · 2024: 110 · 2023: 89 · 2022: 114 · 2021: 125 · 2020: 136 · 2019: 141 · 2018: 129 · 2017: 135 · 2016: 121 · 2015: 146 · 2014: 131 · 2013: 130 · 2012: 136
- FWCI
- 85.14
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Annals of Neurology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- University of Pennsylvania
- National Institutes of Health (5u01ag024904-10)
- National Institute on Aging (U01-AG-024904, AG 024904, P30AG010124, AG-10124, U19AG010483, U19AG024904)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Keywords
- Alzheimer's disease, cerebrospinal fluid biomarkers, amyloid-beta 42, total tau, mild cognitive impairment, conversion to Alzheimer's disease, APOE ε4, Alzheimer's Disease Neuroimaging Initiative
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Cognition Disorders, Diagnostic Imaging, Female, Humans, Male, Middle Aged, Peptide Fragments, Phosphorylation, Retrospective Studies, ROC Curve, Sensitivity and Specificity, Threonine, Cohort Studies, Biomarkers, Amyloid beta-Peptides, tau Proteins, Disease Progression, Statistics, Nonparametric, Area Under Curve, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
